Kossor D C, Meunier P C, Dulik D M, Leonard T B, Goldstein R S
Department of Toxicology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA.
Toxicol Appl Pharmacol. 1998 Oct;152(2):327-38. doi: 10.1006/taap.1998.8507.
Biliary obstruction, produced by common bile duct ligation or alpha-naphthylisothiocyanate (ANIT) treatment in rats, has been associated with the development of type I biliary epithelial cell (BEC) hyperplasia. However, the exact mechanism(s) by which bile duct obstruction lead(s) to this proliferative lesion are not clear. The present studies were designed to determine if cholestasis, in the absence of biliary obstruction, would result in type I BEC hyperplasia. Male Sprague-Dawley rats were given a single oral dose of 150 mg/kg ANIT or i.v. doses of estradiol glucuronide (E2-17G; 21 mumol/kg/h for 48 h) to produce obstructive and non-obstructive cholestasis, respectively. E2-17G treatment resulted in cholestasis that was comparable in extent and duration to that observed following ANIT treatment. E2-17G and ANIT treatments produced comparable increases in serum bile acids (55- to 60-fold) and activities of ALT (36- to 38-fold), ALP (4- to 5-fold), and 5'-nucleotidase (7- to 11-fold), respectively, compared to controls. Both ANIT and E2-17G also increased serum bilirubin concentrations. ANIT treatment resulted in significant increases in biliary glucose concentrations that were associated with BEC damage/necrosis and obstruction of the bile duct lumen. Conversely, no evidence of BEC damage was observed in E2-17G-treated rats. Nonetheless, BEC hyperplasia was observed in the majority of rats following treatment with either ANIT or E2-17G, assessed by light microscopy and by BrdU immunohistochemistry. These data indicate that E2-17G treatment produces nonobstructive cholestasis and type I BEC hyperplasia, suggesting that biliary obstruction is not a prerequisite for type I BEC hyperplasia in rats. Differences in the time of onset of hyperplasia were observed: hyperplasia was noted immediately following 48 h of E2-17G-induced cholestasis but occurred several days after ANIT-induced cholestasis had subsided. Since the magnitude/duration of cholestasis was similar in the two models but the temporal association between cholestasis and type I BEC hyperplasia were different, these data suggest that the proliferative stimulus may be different in the two models and that E2-17G-induced type I BEC hyperplasia may not be attributed solely to cholestasis.
在大鼠中,通过胆总管结扎或α-萘基异硫氰酸酯(ANIT)处理所产生的胆管梗阻,与I型胆管上皮细胞(BEC)增生的发生有关。然而,胆管梗阻导致这种增殖性病变的确切机制尚不清楚。本研究旨在确定在无胆管梗阻的情况下,胆汁淤积是否会导致I型BEC增生。给雄性Sprague-Dawley大鼠单次口服150 mg/kg ANIT或静脉注射雌二醇葡萄糖醛酸苷(E2-17G;21 μmol/kg/h,持续48小时),分别产生梗阻性和非梗阻性胆汁淤积。E2-17G处理导致的胆汁淤积在程度和持续时间上与ANIT处理后观察到的相当。与对照组相比,E2-17G和ANIT处理分别使血清胆汁酸增加了55至60倍,谷丙转氨酶(ALT)活性增加了36至38倍,碱性磷酸酶(ALP)活性增加了4至5倍,5'-核苷酸酶活性增加了7至11倍。ANIT和E2-17G还均增加了血清胆红素浓度。ANIT处理导致胆汁葡萄糖浓度显著增加,这与BEC损伤/坏死以及胆管腔梗阻有关。相反,在E2-17G处理的大鼠中未观察到BEC损伤的证据。尽管如此,通过光学显微镜和BrdU免疫组织化学评估,在大多数用ANIT或E2-17G处理的大鼠中均观察到了BEC增生。这些数据表明,E2-17G处理产生非梗阻性胆汁淤积和I型BEC增生,提示胆管梗阻不是大鼠I型BEC增生的先决条件。观察到增生开始时间的差异:在E2-17G诱导的胆汁淤积48小时后立即注意到增生,但在ANIT诱导的胆汁淤积消退几天后才出现。由于两种模型中胆汁淤积的程度/持续时间相似,但胆汁淤积与I型BEC增生之间的时间关联不同,这些数据表明两种模型中的增殖刺激可能不同,并且E2-17G诱导的I型BEC增生可能不仅仅归因于胆汁淤积。